Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 7
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Dalai, Sarat Kumar Yadav, Naveen Patidar, Manoj Patel, Hardik and Singh, Agam Prasad 2015. Liver-Stage Specific Response among Endemic Populations: Diet and Immunity. Frontiers in Immunology, Vol. 6,

    Burt, A. 2014. Heritable strategies for controlling insect vectors of disease. Philosophical Transactions of the Royal Society B: Biological Sciences, Vol. 369, Issue. 1645, p. 20130432.

    Spring, Michele Murphy, Jittawadee Nielsen, Robin Dowler, Megan Bennett, Jason W. Zarling, Stasya Williams, Jack de la Vega, Patricia Ware, Lisa Komisar, Jack Polhemus, Mark Richie, Thomas L. Epstein, Judy Tamminga, Cindy Chuang, Ilin Richie, Nancy O’Neil, Michael Heppner, D. Gray Healer, Julie O’Neill, Matthew Smithers, Hannah Finney, Olivia C. Mikolajczak, Sebastian A. Wang, Ruobing Cowman, Alan Ockenhouse, Christian Krzych, Urszula and Kappe, Stefan H.I. 2013. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine, Vol. 31, Issue. 43, p. 4975.

    Goyal, Manish Singh, Priyanka Alam, Athar Kumar Das, Sajal Shameel Iqbal, Mohd Dey, Sumanta Bindu, Samik Pal, Chinmay Kumar Das, Sanjit Panda, Gautam and Bandyopadhyay, Uday 2012. Aryl aryl methyl thio arenes prevent multidrug-resistant malaria in mouse by promoting oxidative stress in parasites. Free Radical Biology and Medicine, Vol. 53, Issue. 1, p. 129.

    Vaughan, Ashley M. Mikolajczak, Sebastian A. Wilson, Elizabeth M. Grompe, Markus Kaushansky, Alexis Camargo, Nelly Bial, John Ploss, Alexander and Kappe, Stefan H.I. 2012. Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. Journal of Clinical Investigation, Vol. 122, Issue. 10, p. 3618.

    Irvine, D.J. and Jewell, C.M. 2011. Comprehensive Biomaterials.

    Kappe, S. H. I. Vaughan, A. M. Boddey, J. A. and Cowman, A. F. 2010. That Was Then But This Is Now: Malaria Research in the Time of an Eradication Agenda. Science, Vol. 328, Issue. 5980, p. 862.

  • Expert Reviews in Molecular Medicine, Volume 11
  • 2009, e39

Advances and challenges in malaria vaccine development

  • Ruobing Wang (a1), Joseph D. Smith (a1) and Stefan H.I. Kappe (a1)
  • DOI:
  • Published online: 16 December 2009

Malaria remains one of the most devastating infectious diseases that threaten humankind. Human malaria is caused by five different species of Plasmodium parasites, each transmitted by the bite of female Anopheles mosquitoes. Plasmodia are eukaryotic protozoans with more than 5000 genes and a complex life cycle that takes place in the mosquito vector and the human host. The life cycle can be divided into pre-erythrocytic stages, erythrocytic stages and mosquito stages. Malaria vaccine research and development faces formidable obstacles because many vaccine candidates will probably only be effective in a specific species at a specific stage. In addition, Plasmodium actively subverts and escapes immune responses, possibly foiling vaccine-induced immunity. Although early successful vaccinations with irradiated, live-attenuated malaria parasites suggested that a vaccine is possible, until recently, most efforts have focused on subunit vaccine approaches. Blood-stage vaccines remain a primary research focus, but real progress is evident in the development of a partially efficacious recombinant pre-erythrocytic subunit vaccine and a live-attenuated sporozoite vaccine. It is unlikely that partially effective vaccines will eliminate malaria; however, they might prove useful in combination with existing control strategies. Elimination of malaria will probably ultimately depend on the development of highly effective vaccines.

Corresponding author
*Corresponding author: Stefan Kappe, Seattle Biomedical Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, WA 98109-5219, USA. Tel: +1 206 256 7205; Fax: +1 206 256 7229; E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1C.A. Guerra (2008) The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Medicine 5, e38

2B.M. Greenwood (2008) Control to elimination: implications for malaria research. Trends in Parasitology 24, 449-454

3W.E. Collins and J.W. Barnwell (2009) Plasmodium knowlesi: finally being recognized. Journal of Infectious Diseases 199, 1107-1108

4J. Cox-Singh (2008) Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clinical Infectious Diseases 46, 165-171

5Y. Jin , C. Kebaier and J. Vanderberg (2007) Direct microscopic quantification of dynamics of Plasmodium berghei sporozoite transmission from mosquitoes to mice. Infection and Immunity 75, 5532-5539

6L.H. Miller (2002) The pathogenic basis of malaria. Nature 415, 673-679

7J.K. Baird (2007) Neglect of Plasmodium vivax malaria. Trends in Parasitology 23, 533-539

8K. Marsh and S. Kinyanjui (2006) Immune effector mechanisms in malaria. Parasite Immunology 28, 51-60

9C. Drakeley (2006) The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. Trends in Parasitology 22, 424-430

10S.L. Hoffman (2002) Protection of humans against malaria by immunization with radiation- attenuated Plasmodium falciparum sporozoites. Journal of Infectious Diseases 185, 1155-1164

11R.S. Nussenzweig (1967) Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216, 160-162

12O. Silvie (2002) Effects of irradiation on Plasmodium falciparum sporozoite hepatic development: implications for the design of pre-erythrocytic malaria vaccines. Parasite Immunology 24, 221-223

13D.L. Doolan and S.L. Hoffman (2000) The complexity of protective immunity against liver-stage malaria. Journal of Immunology 165, 1453-1462

14D.F. Clyde (1973) Immunization of man against sporozite-induced falciparum malaria. American Journal of the Medical Sciences 266, 169-177

15K.H. Rieckmann (1974) Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene 68, 258-259

16T.C. Luke and S.L. Hoffman (2003) Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. Journal of Experimental Biology 206, 3803-3808

17R. Chattopadhyay (2009) The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine. Vaccine 27, 3675-3680

18A.K. Mueller (2005) Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433, 164-167

19A.K. Mueller (2005) Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proceedings of the National Academy of Sciences of the United States of America 102, 3022-3027

20A.S. Tarun (2007) Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. Journal of Infectious Diseases 196, 608-616

21S.A. Mikolajczak (2007) L-FABP is a critical host factor for successful malaria liver stage development. International Journal for Parasitology 37, 483-489

22M.F. Good (2005) Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies. Trends in Immunology 26, 295-297

23M.R. van Dijk (2005) Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proceedings of the National Academy of Sciences of the United States of America 102, 12194-12199

24T. Ishino , Y. Chinzei and M. Yuda (2005) Two proteins with 6-cys motifs are required for malarial parasites to commit to infection of the hepatocyte. Molecular Microbiology 58, 1264-1275

25M. Labaied (2007) Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infection and Immunity 75, 3758-3768

26O. Jobe (2007) Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex I-dependent interferon- gamma-producing CD8+ T cells. Journal of Infectious Diseases 196, 599-607

27A.K. Mueller (2007) Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. American Journal of Pathology 171, 107-115

28A.S. Aly (2008) Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Molecular Microbiology 69, 152-163

29B.C. van Schaijk (2008) Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS One 3, e3549

30K.M. VanBuskirk (2009) Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proceedings of the National Academy of Sciences of the United States of America 106, 13004-13009

31E. Belnoue (2004) Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. Journal of Immunology 172, 2487-2495

32E.D. Putrianti (2009) Vaccine-like immunity against malaria by repeated causal-prophylactic treatment of liver-stage Plasmodium parasites. Journal of Infectious Diseases 199, 899-903

33M. Roestenberg (2009) Protection against a malaria challenge by sporozoite inoculation. New England Journal of Medicine 361, 468-477

34C. Ocana-Morgner , M.M. Mota and A. Rodriguez (2003) Malaria blood stage suppression of liver stage immunity by dendritic cells. Journal of Experimental Medicine 197, 143-151

35J.C. Hafalla (2007) Efficient development of plasmodium liver stage-specific memory CD8+ T cells during the course of blood-stage malarial infection. Journal of Infectious Diseases 196, 1827-1835

36J.B. Dame (1984) Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225, 593-599

37V. Enea (1984) DNA cloning of Plasmodium falciparum circumsporozoite gene: amino acid sequence of repetitive epitope. Science 225, 628-630

38J.A. Stoute (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. New England Journal of Medicine 336, 86-91

40P.L. Alonso (2005) Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366, 2012-2018

41P.L. Alonso (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364, 1411-1420

42J.J. Aponte (2007) Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370, 1543-1551

43G. De Becker (2000) The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. International Immunology 12, 807-815

44A. Lalvani (1999) Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. Journal of Infectious Diseases 180, 1656-1664

45J.A. Stoute (1998) Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. Journal of Infectious Diseases 178, 1139-1144

46R. Wang (2004) Induction in Humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. Journal of Immunology 172, 5561-5569

47S.E. Bongfen (2009) The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 27, 328-335

48S.J. Dunachie (2006) A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infection and Immunity 74, 5933-5942

49P. Bejon (2006) A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clinical Trials 1, e29

50V.S. Moorthy (2004) A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Medicine 1, e33

51A. Brave (2007) Vaccine delivery methods using viral vectors. Molecular Pharmaceutics 4, 18-32

52O.J. Ophorst (2007) Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine 25, 6501-6510

53R. Vogels (2007) High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector. Journal of General Virology 88, 2915-2924

54J.P. Shott (2008) Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. Vaccine 26, 2818-2823

55A. Reyes-Sandoval (2008) Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. European Journal of Immunology 38, 732-741

56S.P. Buchbinder (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893

57K.A. Kumar (2006) The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444, 937-940

58A.C. Gruner (2007) Sterile protection against malaria is independent of immune responses to the circumsporozoite protein. PLoS One 2, e1371

59S. Chakravarty (2007) CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nature Medicine 13, 1035-1041

60K. Bucci (2000) Influence of age and HLA type on interferon-gamma (IFN-gamma) responses to a naturally occurring polymorphic epitope of Plasmodium falciparum liver stage antigen-1 (LSA-1). Clinical and Experimental Immunology 122, 94-100

61O.A. Erunkulu (1992) Severe malaria in Gambian children is not due to lack of previous exposure to malaria. Clinical and Experimental Immunology 89, 296-300

63A. Rodriguez (2008) Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1. Infection and Immunity 76, 1709-1718

66B.L. Perlaza (2008) Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver-stage antigen-3-derived long synthetic peptides. European Journal of Immunology 38, 2610-2615

67B.L. Perlaza (2003) Immunogenicity and protective efficacy of Plasmodium falciparum liver-stage Ag-3 in Aotus lemurinus griseimembra monkeys. European Journal of Immunology 33, 1321-1327

68P. Daubersies (2008) Genetic immunisation by liver stage antigen 3 protects chimpanzees against malaria despite low immune responses. PLoS One 3, e2659

69F.M. Thompson (2008) Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 3, e1493

70D.L. Doolan (2003) Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proceedings of the National Academy of Sciences of the United States of America 100, 9952-9957

71S.J. Draper (2009) Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host and Microbe 5, 95-105

73K.A. Kumar (2009) onserved protective mechanisms in radiation and genetically attenuated uis3(−) and uis4(−) plasmodium sporozoites. PLoS One 4, e4480

74M. Tsuji and F. Zavala (2003) T cells as mediators of protective immunity against liver stages of Plasmodium. Trends in Parasitology 19, 88-93

75M.G. Overstreet (2008) Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunological Reviews 225, 272-283

76L.H. Carvalho (2002) IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages. Nature Medicine 8, 166-170

77W.R. Weiss (1988) CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proceedings of the National Academy of Sciences of the United States of America 85, 573-576

79M.M. Rodrigues (1991) CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. International Immunology 3, 579-585

80P. Romero (1989) Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341, 323-326

82B. Wizel (1995) Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. Journal of Experimental Medicine 182, 1435-1445

83S.E. Bongfen (2007) Plasmodium berghei-infected primary hepatocytes process and present the circumsporozoite protein to specific CD8+ T cells in vitro. Journal of Immunology 178, 7054-7063

84W.R. Weiss (1990) Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. Journal of Experimental Medicine 171, 763-773

87M.C. Seguin (1994) Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. Journal of Experimental Medicine 180, 353-358

88E.G. Rodrigues (2000) Interferon-gamma-independent CD8+ T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus. Parasite Immunology 22, 157-160

89S. Chakravarty (2008) Effector CD8+ T lymphocytes against liver stages of Plasmodium yoelii do not require gamma interferon for antiparasite activity. Infection and Immunity 76, 3628-3631

90A. Trimnell (2009) Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes. Journal of Immunology 183, 5870-5878

91O. Jobe (2009) Immunization with radiation-attenuated Plasmodium berghei sporozoites induces liver cCD8alpha + DC that activate CD8 + T cells against liver-stage malaria. PLoS One 4, e5075

92M. Plebanski (2005) Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 T-cell responses. Immunology and Cell Biology 83, 307-312

93S.E. Bongfen (2008) Processing of the circumsporozoite protein in infected hepatocytes is not dependent on aspartic proteases. Parasite Immunology 30, 375-378

94I. Usynin , C. Klotz and U. Frevert (2007) Malaria circumsporozoite protein inhibits the respiratory burst in Kupffer cells. Cellular Microbiology 9, 2610-2628

95A.P. Singh (2007) Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 131, 492-504

96S.M. Todryk (2008) Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS One 3, e2027

98D. Berenzon (2003) Protracted protection to Plasmodium berghei malaria is linked to functionally and phenotypically heterogeneous liver memory CD8+ T cells. Journal of Immunology 171, 2024-2034

99N.W. Schmidt (2008) Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proceedings of the National Academy of Sciences of the United States of America 105, 14017-14022

100J.A. Dvorak (1975) Invasion of erythrocytes by malaria merozoites. Science 187, 748-750

101K. Marsh and R.W. Snow (1997) Host-parasite interaction and morbidity in malaria endemic areas. Philosophical Transactions of the Royal Society of London Series B Biological Sciences 352, 1385-1394

102S. Cohen , G.I. Mc and S. Carrington (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192, 733-737

104P.R. Gilson and B.S. Crabb (2009) Morphology and kinetics of the three distinct phases of red blood cell invasion by Plasmodium falciparum merozoites. International Journal for Parasitology 39, 91-96

105V.K. Goel (2003) Band 3 is a host receptor binding merozoite surface protein 1 during the Plasmodium falciparum invasion of erythrocytes. Proceedings of the National Academy of Sciences of the United States of America 100, 5164-5169

106G.H. Mitchell (2004) Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infection and Immunity 72, 154-158

107L.H. Miller (1979) Interaction between cytochalasin B-treated malarial parasites and erythrocytes. Attachment and junction formation. Journal of Experimental Medicine 149, 172-184

108A.P. Singh (2005) Targeted deletion of Plasmodium knowlesi Duffy binding protein confirms its role in junction formation during invasion. Molecular Microbiology 55, 1925-1934

111C.W. Kauth (2003) The merozoite surface protein 1 complex of human malaria parasite Plasmodium falciparum: interactions and arrangements of subunits. Journal of Biological Chemistry 278, 22257-22264

112C.W. Kauth (2006) Interactions between merozoite surface proteins 1, 6, and 7 of the malaria parasite Plasmodium falciparum. Journal of Biological Chemistry 281, 31517-31527

113M.J. Blackman and A.A. Holder (1992) Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Molecular and Biochemical Parasitology 50, 307-315

114M.J. Blackman (1991) Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Molecular and Biochemical Parasitology 49, 29-33

115E. Angov (2003) Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine. Molecular and Biochemical Parasitology 128, 195-204

116M.J. Blackman (1990) A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. Journal of Experimental Medicine 172, 379-382

117C.C. John (2004) Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. Journal of Immunology 173, 666-672

118I.T. Ling , S.A. Ogun and A.A. Holder (1994) Immunization against malaria with a recombinant protein. Parasite Immunology 16, 63-67

120R.A. O'Donnell (2001) Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. Journal of Experimental Medicine 193, 1403-1412

121R.S. McIntosh (2007) The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathogens 3, e72

123S. Singh (2006) Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infection and Immunity 74, 4573-4580

124U. Woehlbier (2006) Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum. Infection and Immunity 74, 1313-1322

125J.A. Lyon (2008) Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS One 3, e2830

126C.F. Ockenhouse (2006) Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 24, 3009-3017

127J.A. Stoute (2007) Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 25, 176-184

128M.A. Thera (2006) Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clinical Trials 1, e34

129B.R. Ogutu (2009) Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 4, e4708

130J. Healer (2002) Independent translocation of two micronemal proteins in developing Plasmodium falciparum merozoites. Infection and Immunity 70, 5751-5758

131D.L. Narum and A.W. Thomas (1994) Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Molecular and Biochemical Parasitology 67, 59-68

132J. Cao (2009) Rhoptry neck protein RON2 forms a complex with microneme protein AMA1 in Plasmodium falciparum merozoites. Parasitology International 58, 29-35

133C.R. Collins (2009) An inhibitory antibody blocks interactions between components of the malarial invasion machinery. PLoS Pathogens 5, e1000273

134D.L. Alexander (2005) Identification of the moving junction complex of Toxoplasma gondii: a collaboration between distinct secretory organelles. PLoS Pathogens 1, e17

135S. Dutta (2005) Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum. Infection and Immunity 73, 2116-2122

136S. Dutta (2003) Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proceedings of the National Academy of Sciences of the United States of America 100, 12295-12300

137A.N. Hodder , P.E. Crewther and R.F. Anders (2001) Specificity of the protective antibody response to apical membrane antigen 1. Infection and Immunity 69, 3286-3294

138M.C. Kennedy (2002) In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infection and Immunity 70, 6948-6960

139C.H. Kocken (2002) High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infection and Immunity 70, 4471-4476

140A. Dicko (2008) Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PLoS One 3, e1563

141M.D. Spring (2009) Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One 4, e5254

142I. Sagara (2009) A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 27, 3090-3098

143J. Hu (2008) Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. PLoS One 3, e1952

144L.H. Miller (1976) The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. New England Journal of Medicine 295, 302-304

145X.D. Fang (1991) Cloning of the Plasmodium vivax Duffy receptor. Molecular and Biochemical Parasitology 44, 125-132

146C.E. Chitnis and L.H. Miller (1994) Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. Journal of Experimental Medicine 180, 497-506

147B.K. Sim (1994) Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 264, 1941-1944

148A.F. Cowman and B.S. Crabb (2006) Invasion of red blood cells by malaria parasites. Cell 124, 755-766

149J.H. Adams (1990) The Duffy receptor family of Plasmodium knowlesi is located within the micronemes of invasive malaria merozoites. Cell 63, 141-153

150S.K. Singh (2006) Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain. Nature 439, 741-744

151C.E. Chitnis and A. Sharma (2008) Targeting the Plasmodium vivax Duffy-binding protein. Trends in Parasitology 24, 29-34

153J. Xainli , J.H. Adams and C.L. King (2000) The erythrocyte binding motif of Plasmodium vivax duffy binding protein is highly polymorphic and functionally conserved in isolates from Papua New Guinea. Molecular and Biochemical Parasitology 111, 253-260

154K.M. VanBuskirk (2004) Antigenic drift in the ligand domain of Plasmodium vivax duffy binding protein confers resistance to inhibitory antibodies. Journal of Infectious Diseases 190, 1556-1562

155C.L. King (2008) Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proceedings of the National Academy of Sciences of the United States of America 105, 8363-8368

156S. Singh (2001) Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax duffy-binding protein. Journal of Biological Chemistry 276, 17111-17116

157Y.S. Devi (2007) Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice. Vaccine 25, 5166-5174

158P. Michon , T. Fraser and J.H. Adams (2000) Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein. Infection and Immunity 68, 3164-3171

159S.S. Yazdani (2004) Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein. Vaccine 22, 3727-3737

160B.T. Grimberg (2007) Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Medicine 4, e337

162S. Kyes , P. Horrocks and C. Newbold (2001) Antigenic variation at the infected red cell surface in malaria. Annual Review of Microbiology 55, 673-707

163S.M. Kraemer and J.D. Smith (2006) A family affair: var genes, PfEMP1 binding, and malaria disease. Current Opinion in Microbiology 9, 374-380

164R. Udomsangpetch (2002) Febrile temperatures induce cytoadherence of ring-stage Plasmodium falciparum-infected erythrocytes. Proceedings of the National Academy of Sciences of the United States of America 99, 11825-11829

165D.I. Baruch (1999) Adhesive receptors on malaria-parasitized red cells. Baillieres Best Pract Res Clinics in Haematology 12, 747-761

166X.Z. Su (1995) The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 82, 89-100

167M.J. Gardner (2002) Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498-511

168J.D. Smith (1995) Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82, 101-110

169B.J. Brabin (2004) The sick placenta - the role of malaria. Placenta 25, 359-378

171M.F. Duffy (2006) Transcribed var genes associated with placental malaria in Malawian women. Infection and Immunity 74, 4875-4883

172P. Magistrado (2008) VAR2CSA expression on the surface of placenta-derived Plasmodium falciparum-infected erythrocytes. Journal of Infectious Diseases 198, 1071-1074

173A. Salanti (2003) Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Molecular Microbiology 49, 179-191

174N.G. Tuikue Ndam (2005) High level of var2csa transcription by Plasmodium falciparum isolated from the placenta. Journal of Infectious Diseases 192, 331-335

175A.R. Trimnell (2006) Global genetic diversity and evolution of var genes associated with placental and severe childhood malaria. Molecular and Biochemical Parasitology 148, 169-180

176M. Avril (2008) Evidence for globally shared, cross-reacting polymorphic epitopes in the pregnancy-associated malaria vaccine candidate VAR2CSA. Infection and Immunity 76, 1791-1800

177L. Barfod (2006) Baculovirus-expressed constructs induce immunoglobulin G that recognizes VAR2CSA on Plasmodium falciparum-infected erythrocytes. Infection and Immunity 74, 4357-4360

178P. Fernandez (2008) Var2CSA DBL6-epsilon domain expressed in HEK293 induces limited cross-reactive and blocking antibodies to CSA binding parasites. Malaria Journal 7, 170

179M.A. Nielsen (2009) Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA. Infection and Immunity 77, 2482-2487

180A.V. Oleinikov (2008) VAR2CSA domains expressed in Escherichia coli induce cross-reactive antibodies to native protein. Journal of Infectious Diseases 197, 1119-1123

181J.G. Beeson (2006) Antigenic differences and conservation among placental Plasmodium falciparum-infected erythrocytes and acquisition of variant-specific and cross-reactive antibodies. Journal of Infectious Diseases 193, 721-730

182J. Bockhorst (2007) Structural polymorphism and diversifying selection on the pregnancy malaria vaccine candidate VAR2CSA. Molecular and Biochemical Parasitology 155, 103-112

183M. Fried (1998) Maternal antibodies block malaria. Nature 395, 851-852

184L. Barfod (2007) Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA. Molecular Microbiology 63, 335-347

185P. Andersen (2008) Structural insight into epitopes in the pregnancy-associated malaria protein VAR2CSA. PLoS Pathogens 4, e42

186P.E. Duffy and M. Fried (2003) Antibodies that inhibit Plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newborns. Infection and Immunity 71, 6620-6623

187I. O'Neil-Dunne (2001) Gravidity-dependent production of antibodies that inhibit binding of Plasmodium falciparum-infected erythrocytes to placental chondroitin sulfate proteoglycan during pregnancy. Infection and Immunity 69, 7487-7492

188C.H. Ricke (2000) Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block parasite adhesion to chondroitin sulfate A. Journal of Immunology 165, 3309-3316

189A. Jaworowski (2009) Relationship between human immunodeficiency virus type 1 coinfection, anemia, and levels and function of antibodies to variant surface antigens in pregnancy-associated malaria. Clinical and Vaccine Immunology 16, 312-319

190J. Keen (2007) HIV impairs opsonic phagocytic clearance of pregnancy-associated malaria parasites. PLoS Medicine 4, e181

191A.M. Mount (2004) Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 363, 1860-1867

192T. Staalsoe (2004) Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet 363, 283-289

193G. Krishnegowda (2005) Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. Journal of Biological Chemistry 280, 8606-8616

194L. Schofield and F. Hackett (1993) Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites. Journal of Experimental Medicine 177, 145-153

195P. Parroche (2007) Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proceedings of the National Academy of Sciences of the United States of America 104, 1919-1924

196G.E. Grau (1989) Tumor necrosis factor and disease severity in children with falciparum malaria. New England Journal of Medicine 320, 1586-1591

197D. Kwiatkowski (1990) TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 336, 1201-1204

198L. Schofield (1996) Glycosylphosphatidylinositol toxin of Plasmodium up-regulates intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin expression in vascular endothelial cells and increases leukocyte and parasite cytoadherence via tyrosine kinase-dependent signal transduction. Journal of Immunology 156, 1886-1896

199L. Schofield (2002) Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 418, 785-789

200A.S. Tarun (2006) Quantitative isolation and in vivo imaging of malaria parasite liver stages. International Journal for Parasitology 36, 1283-1293

201A.S. Tarun (2008) A combined transcriptome and proteome survey of malaria parasite liver stages. Proceedings of the National Academy of Sciences of the United States of America 105, 305-310

202G. Corradin (2007) Peptide based malaria vaccine development: personal considerations. Microbes and Infection 9, 767-771

203D. Haddad (2004) Novel antigen identification method for discovery of protective malaria antigens by rapid testing of DNA vaccines encoding exons from the parasite genome. Infection and Immunity 72, 1594-1602

204R. Wang (2005) Immune responses to Plasmodium vivax pre-erythrocytic stage antigens in naturally exposed Duffy-negative humans: a potential model for identification of liver-stage antigens. European Journal of Immunology 35, 1859-1868

205B. Greenwood , K. Marsh and R. Snow (1991) Why do some African children develop severe malaria? Parasitology Today 7, 277-281

206L.A. Koutsky (2002) A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine 347, 1645-1651

207G. Di Giulio (2009) Live immunization against East Coast fever-current status. Trends in Parasitology 25, 85-92

J.P. Vanderberg (2009) Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond. Vaccine 27, 2-9

R.R. Dinglasan and M. Jacobs-Lorena (2008) Flipping the paradigm on malaria transmission-blocking vaccines. Trends in Parasitology 24, 364-370

C. Lavazec and C. Bourgouin (2008) Mosquito-based transmission blocking vaccines for interrupting Plasmodium development. Microbes and Infection 10, 845-849

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *